Log in

Relevant bibliographies by topics / Dithranol

Contents

Journal articles
Dissertations / Theses
Book chapters

Academic literature on the topic 'Dithranol'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dithranol.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Dithranol"

1

&NA;. "Dithranol." Reactions Weekly &NA;, no. 772 (October 1999): 7. http://dx.doi.org/10.2165/00128415-199907720-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Dithranol." Reactions Weekly &NA;, no. 440 (February 1993): 8. http://dx.doi.org/10.2165/00128415-199304400-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mahrle, Gustav. "Dithranol." Clinics in Dermatology 15, no. 5 (September 1997): 723–37. http://dx.doi.org/10.1016/s0738-081x(97)00019-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Dithranol." Reactions Weekly &NA;, no. 400 (May 1992): 7. http://dx.doi.org/10.2165/00128415-199204000-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chavali, Krishnadutt H., and Harish Dasari. "Dithranol." American Journal of Forensic Medicine and Pathology 33, no. 3 (September 2012): 253–55. http://dx.doi.org/10.1097/paf.0b013e3182198659.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Dithranol." Reactions Weekly &NA;, no. 1388 (February 2012): 14. http://dx.doi.org/10.2165/00128415-201213880-00052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Melhorn, S. "Dithranol." Der Hautarzt 68, no. 5 (April 11, 2017): 421–23. http://dx.doi.org/10.1007/s00105-017-3977-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

C, Anahera, and Kahurangi S. "Development of Dithranol overloaded hard Lipid Nanoparticles." International Journal of Pharmacy and Biomedical Engineering 2, no. 3 (December 25, 2015): 5–8. http://dx.doi.org/10.14445/23942576/ijpbe-v2i3p102.

Full text

Abstract:

Dithranol belongs to the keratolytic category, which is widely used drug in the treatment of psoriasis. The drug is virtually inexplicable in water. Many conservative quantity forms for psoriasis treatment have been have been formulated earlier, but they did not show good results. Hence in the present study, it was attempted to invent dithranol in the form of solid lipid nanoparticle. Solid lipid nanoparticles of dithranol were obtained by alteration of lipid spreading method. Preformulation studies were performed to check the compatibility of drug and excepient for the development of formulation by DSC and no statement was found. Solubility study, division coefficient purpose, UV examination, HPLC study, FTIR study were also performed. After the preformulation studies Dithranol loaded solid lipid nanoparticles was also prepared. Hence it was concluded that solid lipid nanoparticle of dithranol could be formulated.

APA, Harvard, Vancouver, ISO, and other styles

9

Prins, M., O. Q. J. Swinkels, J. M. Mommers, M. J. P. Gerritsen, and P. G. M. Valk. "Dithranol treatment of psoriasis in dithranol-sensitive patients." Contact Dermatitis 41, no. 2 (May 1, 2007): 116–17. http://dx.doi.org/10.1111/j.1600-0536.1999.tb06250.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Legradi, Adam, Karolina Dulka, Gábor Jancsó, and Karoly Gulya. "Orofacial skin inflammation increases the number of macrophages in the maxillary subregion of the rat trigeminal ganglion in a corticosteroid-reversible manner." Cell and Tissue Research 382, no. 3 (July 21, 2020): 551–61. http://dx.doi.org/10.1007/s00441-020-03244-3.

Full text

Abstract:

AbstractInflammation of the cutaneous orofacial tissue can lead to a prolonged alteration of neuronal and nonneuronal cellular functions in trigeminal nociceptive pathways. In this study, we investigated the effects of experimentally induced skin inflammation by dithranol (anthralin) on macrophage activation in the rat trigeminal ganglion. Tissue localization and protein expression levels of ionized calcium-binding adaptor molecule 1 (Iba1), a macrophage/microglia-specific marker, and proliferation/mitotic marker antigen identified by the monoclonal antibody Ki67 (Ki67), were quantitatively analyzed using immunohistochemistry and western blots in control, dithranol-treated, dithranol- and corticosteroid-treated, and corticosteroid-treated trigeminal ganglia. Chronic orofacial dithranol treatment elicited a strong pro-inflammatory effect in the ipsilateral trigeminal ganglion. Indeed, daily dithranol treatment of the orofacial skin for 3–5 days increased the number of macrophages and Iba1 protein expression in the maxillary subregion of the ipsilateral ganglion. In the affected ganglia, none of the Iba1-positive cells expressed Ki67. This absence of mitotically active cells suggested that the accumulation of macrophages in the ganglion was not the result of resident microglia proliferation but rather the extravasation of hematogenous monocytes from the periphery. Subsequently, when a 5-day-long anti-inflammatory corticosteroid therapy was employed on the previously dithranol-treated orofacial skin, Iba1 immunoreactivity was substantially reduced in the ipsilateral ganglion. Collectively, our findings indicate that both peripheral inflammation and subsequent anti-inflammatory therapy affect macrophage activity and thus interfere with the functioning of the affected sensory ganglion neurons.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Dithranol"

1

McBride, Sandra R. "The inflammatory response to dithranol." Thesis, University of Newcastle upon Tyne, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.421173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lubwika, Paul. "A stability study of dithranol in solution, formulations and in normal and psoriatic skin." Thesis, Robert Gordon University, 1994. http://hdl.handle.net/10059/2348.

Full text

Abstract:

For more than 100 years dithranol has been successfully used for the treatment of psoriasis . It is still not fully understood, however, how it exerts its antipsoriatic effect. From the information available to date it is clear that the actual process of decomposition is central to the therapeutic action of dithranol. Since there is an obvious parallel between the mechanism of decomposition in solution and that of decomposition/metabolism in skin stability studies were carried out in aqueous buffer (PH 5.5). The effect of various factors such as the presence of various metal ions and surfactants on the decomposition pattern (individual rates of dimer and danthron formation) of dithranol in solution were quantified. The effect of, in particular, surfactants on the skin permeation and decomposition/metabolism of dithranol were then investigated. Because of dithranol's poor water solubility it was necessary to develop an analytical technique capable of the successful quantification of low levels of dithranol and breakdown products in aqueous systems. A previously reported hplc system, which has adequate sensitivity for dithranol and danthron quantification, was used. Improved sensitivity for dimer (3 fold increase), thus allowing the accurate quantification of low levels of dimer in aqueous solutions, was achieved by a modification of the mobile phase. As it was also necessary to establish the amounts of dithranol and breakdown products on and in skin an appropriate extraction method was needed. A procedure whereby skin was first extracted using a mixture of trichloro acetic acid and methanol followed by hplc analysis of the extract was developed. Surfactant solubilisation of dithranol was used to enhance the water solubility of dithranol. Data from the solubilisation studies shows that in sodium lauryl sulphate and tween 80 (above c. m.c in aqueous buffer pH 5.5) the amount of dithranol in solution is directly proportional to the % of surfactant present. In cetrimide, solubilisatiori was observed only at low pH e.g pH 0.4. At pH 5.5, because of the interaction that takes place between dithranol and cetrimide causing dithranol to ionise, dithranol ionisation is responsible for enhanced solubility. About 3 fold more dithranol goes into such cetrimide solutions compared to equivalent concentrations of sodium lauryl sulphate and tween 80. Surfactant presence, however, had implications on dithranol's decomposition pattern. In the sodium lauryl sulphate and tween 80 solutions little change from that seen in buffer pH 5.5 was observed namely - 94 % dimer and - 4 % danthron were produced following complete decomposition. In the presence of cetrimide (PH 5.5) a marked change was seen with - 84% danthron and -14% dimer being formed on complete decomposition. The effect of the inclusion of metal ions i.e Cu2+, Zn2+ and Fe2+ on the kinetics of the decomposition of dithranol to dimer and danthron were quantified. All had a catalytic effect on the rate of dimer formation, while suppressing that of danthron. The catalytic coefficients were in the order of Cu2+ > Fe2+ > Zn2+. Concentration vs time data generated on placing surfactant solutions of dithranol in contact with animal skin (in vitro) and human skin (in vivo) allowed estimates of the amount of dithranol and breakdown products penetrating into the skin, along with the degree of skin surface decomposition taking place during the permeation process. A pronounced deviation was observed for dithranol decomposition in the formulations on the skin and when not in contact with skin. Skin surface decomposition was found to result in the formation of an ,as yet unknown, breakdown product (P4). Using the 12-0-tetradecanoylphorbol-13-acetate/hairless mouse psonasls model it was visually established that the cetrimide-dithranol formulation negated the anti inflammatory effects of dithranol . The tween 80 and sodium lauryl sulphate dithranol formulations reduced the inflammatory response in the psoriasis model to the same degree as an equivalent amount of dithranol delivered in acetone. A preliminary clinical investigation on the influence of cetrimide on the therapeutic outcome of conventional dithranol therapy was carried out using two patients with psoriasis. Cleansing the skin with a solution of cetrimide before and after treatment with dithranol resulted in both a reduction of side effects and a loss in the therapeutic effectiveness of dithranol. The data gathered allowed the discussion of the effect of dithranol's decomposition pathway on its therapeutic outcome.

APA, Harvard, Vancouver, ISO, and other styles

3

Priprem, Aroonsri. "The development and evaluation of a hydrogel drug delivery system for dithranol." Thesis, Robert Gordon University, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.278936.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Reindl, Hans. "Synthese und Charakterisierung bei der biologischen Aktivität neuer 10-Acylderivate des Antipsoriatikums Dithranol /." [S.l. : s.n.], 1999. http://www.gbv.de/dms/bs/toc/301413681.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Milner, Sarah Elizabeth. "The effects of the anti-psoriatic agent dithranol on intracellular calcium signalling in keratinocytes." Thesis, University of Newcastle Upon Tyne, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.501057.

Full text

Abstract:

Psoriasis is a common chronic inflammatory disease of the skin and affects 2 % of the Western population. It is characterised by increased keratinocyte proliferation, abnormal keratinocyte differentiation and an infiltration of lymphocytes and neutrophils but to date the aetiology of psoriasis remains incompletely understood. Several lines of evidence indicate a fundamental defect in calcium signalling in keratinocytes. Previous research has shown that keratinocytes cultured from uninvolved psoriatic skin show enhanced cellular calcium responses to calcium-mobilising agonists. The presence of a calcium gradient within the epidermis has also been reported and both intracellular and extracellular calcium have been implicated in the regulation of keratinocyte proliferation and differentiation. It is reported that this gradient is lost in psoriatic skin, further reinforcing the concept of a primary defect within psoriatic skin.

APA, Harvard, Vancouver, ISO, and other styles

6

Tait, Russell John, and mikewood@deakin edu au. "Development and application of a microelectrode based scanning voltammetric detector." Deakin University. School of Physical and Chemical Sciences, 1991. http://tux.lib.deakin.edu.au./adt-VDU/public/adt-VDU20060720.100447.

Full text

Abstract:

A large part of the work presented in this thesis describes the development and use of a novel electrochemical detector designed to allow the electrochemical characterisation of compounds in flowing solution by means of cyclic voltammetry. The detector was microprocessor controlled, which provides digital generation of the potential waveform and collection of data for subsequent analysis. Microdisk working electrodes are employed to permit both thermodynamic and kinetically controlled processes to be studied under steady-state conditions in flowing solutions without the distortion or hysteresis normally encountered with larger sized electrodes. The effect of electrode size, potential scan rate, and solution flow rate are studied extensively with the oxidation of ferrocene used as an example of a thermodynamically controlled process and a series of catecholamines as examples of a kinetically controlled process. The performance of the detector was best demonstrated when used as a HPLC post-column detector. The 3-dimensional chromatovoltammograms obtained allow on-line characterisation of each fraction as it elutes from the column. The rest of the work presented in this thesis involves the study of the oxidative degradation pathway of dithranol. The oxidative pathway was shown to involve a complex free radical mechanism, dependent on the presence of both oxygen and, in particular light. The pathway is further complicated by the fact that dithranol may exist in either a keto or enol form, the enol being most susceptible to oxidation. A likely mechanism is proposed from studies performed with cyclic voltammetry and controlled potential electrolysis, then defined by subsequent kinetic studies.

APA, Harvard, Vancouver, ISO, and other styles

7

Savian, Ana Luiza. "DESENVOLVIMENTO DE NANOCÁPSULAS CONTENDO DITRANOL E SUA INCORPORAÇÃO EM FORMULAÇÃO SEMISSÓLIDA DE BASE AQUOSA." Universidade Federal de Santa Maria, 2012. http://repositorio.ufsm.br/handle/1/5979.

Full text

Abstract:

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Dithranol is very effective drug for the topical treatment of psoriasis. However, it has some adverse effects, such as irritation and stain in the skin that difficult its application and patient adherence to treatment. Its instability to light, high pH values, metals and the presence of oxygen, configure as a limiting step for use. So, the inclusion of drug in nanocarriers was the main objective of this work. Lipid core nanocapsules and nanoemulsions containing 0.5 mg/mL of dithranol and 0.05% of EDTA or 0.02% of ascorbic acid were prepared by interfacial deposition of preformed polymer and spontaneous emulsification methods, respectively, and evaluated in relation to its physicochemical characteristics (drug content, encapsulation efficiency, pH, mean size, polydispersity index and zeta potential). The nanocapsules, after preparation, showed satisfactory characteristics: drug content near to the theoretical concentration, encapsulation efficiency about 100%, nanometric mean size (220- 250 nm), polydispersity index below 0.25, negative zeta potential, and pH values from 5.6 to 4.4. Instead, low drug content was verified for the nanoemulsions (approximately 80%) after preparation. In photodegradation study against UVA light it was observed a higher stability of the dithranol-loaded nanocapsules comparing to solution containing the free drug (t1/2 = 4 and 1 h for nanocapsule and free drug solution containing EDTA, respectively; t1/2 = 17 and 7,5 h for nanocapsule and free drug solution containing ascorbic acid, respectively). Irritation test by HET-CAM method was conducted to evaluate the safety of the formulations. From the results it was found that nanoencapsulation of the drug decreased its toxicity compared to the effects observed for free drug. Subsequently, hydrogels containing nanocapsules were prepared employing Carbopol® 940 and Aristoflex® AVC as gel-forming polymers. The semisolid formulations showed suitable properties for topical application and higher stability when compared to nanocapsules suspensions and the hydrogel containing the free drug. Furthermore, a higher stability of dithranol was verified for hydrogels prepared with Aristoflex® AVC.
O ditranol é um fármaco muito eficaz no tratamento tópico da psoríase. Entretanto, apresenta alguns efeitos adversos, como irritação e manchas na pele que dificultam sua utilização e adesão dos pacientes ao tratamento. Sua instabilidade frente à luz, altos valores de pH, metais e a presença de oxigênio, configuram, também, um passo limitante para o seu uso. Desta forma, a inclusão do fármaco em nanocarreadores constituiu o principal objetivo deste trabalho. Nanocápsulas de núcleo lipídico e nanoemulsões contendo 0,5 mg/mL de ditranol e 0,05% de EDTA ou 0,02% de ácido ascórbico foram preparadas pelos métodos de deposição interfacial do polímero pré-formado e emulsificação espontânea, respectivamente, e avaliadas em relação as suas características físico-químicas (teor de fármaco, eficiência de encapsulamento, pH, diâmetro médio de partícula, polidispersão e potencial zeta). As nanocápsulas, após preparação, apresentaram características satisfatórias: teor de fármaco próximo ao teórico, eficiência de encapsulamento de, aproximadamente, 100%, diâmetro de partícula na faixa nanométrica (220-250 nm), índice de polidispersão abaixo de 0,25, potencial zeta negativo e valores de pH de 5,6 a 4,4. Ao contrário, um baixo teor de fármaco foi verificado para as nanoemulsões (aproximadamente, 80%) após preparação. No estudo de fotodegradação frente à luz UVA se observou uma maior estabilidade do fármaco nas nanocápsulas em comparação à solução do fármaco livre (t1/2 = 4 e 1 hora para a nanocápsula e solução do fármaco livre contendo EDTA, respectivamente; t1/2 = 17 e 7,5 horas para a nanocápsula e solução do fármaco livre contendo ácido ascórbico, respectivamente). O ensaio de irritação pelo método de HET-CAM foi realizado para a avaliação da segurança das formulações. A partir dos resultados verificou-se que a encapsulação do fármaco diminuiu sua toxicidade em relação aos efeitos observados para o fármaco livre. Posteriormente, hidrogéis contendo as nanocápsulas foram preparados empregando-se Carbopol® 940 e Aristoflex® AVC como polímeros formadores de gel. As formulações semissólidas desenvolvidas apresentaram propriedades adequadas para a aplicação tópica e maior estabilidade quando comparadas às suspensões de nanocápsulas e ao hidrogel contendo o fármaco livre. Além disso, uma maior estabilidade do ditranol foi verificada para os hidrogéis preparados com Aristoflex® AVC.

APA, Harvard, Vancouver, ISO, and other styles

8

Wohlrab, Lukas. "Der Einfluß von Harnstoff auf die antiproliferative Wirkung von Dithranol /." 1998. http://www.gbv.de/dms/bs/toc/239950208.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

杜春江. "Synthetic study of 10-substituted dithranol via Base-Catalyed Diels-Alder Cycloaddition." Thesis, 1992. http://ndltd.ncl.edu.tw/handle/91230820188146637939.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Dithranol"

1

Kucharekova, M., PC M. van de Kerkhof, J. Schalkwijk, and P. G. M. van der Valk. "Dithranol." In Irritant Dermatitis, 317–22. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/3-540-31294-3_34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gloor, M. "Dithranol, Vitamin D3-Analoga und 8-Methoxypsoralen." In Dermatologische Externatherapie, 361–93. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-58308-7_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bernd, A., H. Holzmann, W. Ch Marsch, B. Kureleć, S. Britvić, and W. E. G. Müller. "Cytotoxische und anti-mutagene Eigenschaften von Dithranol (= Cignolin) in vitro." In Dermatologie und Rheuma, 545–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72668-2_61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mustakallio, K. K. "Treatment of Psoriasis with Dithranol (Cignolin, Anthralin) and Other Hydroxyanthrones." In Dermatology in Five Continents, 92–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-83360-1_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Przybilla, B., P. Kaudewitz, and K. Bieber. "Harnstoff in Kombination mit Dithranol zur Therapie der Psoriasis vulgaris." In Harnstoff in der Dermatologie, 54–57. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83754-8_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bernd, A., H. Holzmann, H. Ch Schröder, and W. E. G. Müller. "Wirkung von Dithranol und Steinkohlenteer auf den nukleo-cytoplasmatischen Transport der mRNA." In Dermatologie und Rheuma, 548–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72668-2_62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kanerva, L., and J. Lauharanta. "Variable Effects of Irritants (Methylmethacrylate, Terphenyls, Dithranol and Methylglyoxal-bis-Guanylhydrazone) on the Fine Structure of the Epidermis." In Archives of Toxicology, 455. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71248-7_93.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kosma, V. M., Y. Collan, A. Naukkarinen, M. L. Aalto, and P. Männistö. "Histopathological and Morphometrical Analysis Applied to Skin Changes in NMRI Mice Induced by Dithranol (Anthranil) and its Acyl Analogs." In Archives of Toxicology, 451–54. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71248-7_92.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

"Coal tar and Dithranol." In Meyler's Side Effects of Drugs, 487–89. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.01715-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!